Sichuan Kelun-Biotech Biopharmaceutical Future Growth
Future criteria checks 2/6
Sichuan Kelun-Biotech Biopharmaceutical is forecast to grow earnings and revenue by 31.2% and 29% per annum respectively. EPS is expected to grow by 32.8% per annum. Return on equity is forecast to be -22.9% in 3 years.
Key information
31.2%
Earnings growth rate
32.8%
EPS growth rate
Biotechs earnings growth | 34.1% |
Revenue growth rate | 29.0% |
Future return on equity | -22.9% |
Analyst coverage | Good |
Last updated | 24 Jul 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,562 | -34 | -185 | 231 | 10 |
12/31/2025 | 1,549 | -609 | -663 | -456 | 12 |
12/31/2024 | 1,221 | -571 | -880 | -769 | 12 |
12/31/2023 | 1,540 | -522 | -23 | 60 | N/A |
9/30/2023 | 1,523 | -427 | 135 | 207 | N/A |
6/30/2023 | 1,505 | -333 | 292 | 355 | N/A |
3/31/2023 | 1,155 | -440 | -9 | 42 | N/A |
12/31/2022 | 804 | -548 | -310 | -271 | N/A |
12/31/2021 | 32 | -823 | -581 | -486 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6990 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6990 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6990 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6990's revenue (29% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).
High Growth Revenue: 6990's revenue (29% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6990 is forecast to be unprofitable in 3 years.